Tuesday, March 18, 2025 | 01:25 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Moderna shares soar over 16% over coronavirus vaccine trial result

All the 45 patients in the trial produced neutralising antibodies which are believed to be important for building immunity

The government is now trying to understand how long it will take before the drug’s production can start in India
Premium

In May, Moderna announced that the phase I trial of its Covid-19 vaccine has shown positive early results.

ANI
US drugmaker Moderna's shares soared by more than 16 per cent after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, CNBC reported.
All the 45 patients in the trial produced neutralising antibodies which are believed to be important for building immunity and provided more promising data that the vaccine may give some protection against the coronavirus, according to the findings published in the New England Journal of Medicine.
After two vaccinations, the vaccine elicited a "robust" immune response in all participants in all dose cohorts, Moderna

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in